Springer G F, Desai P R, Spencer B D, Tegtmeyer H, Carlstedt S C, Scanlon E F
Heather M. Bligh Cancer Research Laboratories, Chicago Medical School, IL 60064, USA.
Cancer Detect Prev. 1995;19(4):374-80.
Since 1974, and as of March, 1993, we have used T/Tn antigen vaccine in safe, specific, effective, long-term intradermal vaccination against recurrence of advanced breast carcinoma (CA). Staging is by the pathologic TNM system. Treatment is ad infinitum. Of 19 consecutive breast carcinoma patients vaccinated, six Stage IV, six Stage III, and seven Stage II all survived > 5 years postoperatively. Three Stage III, three Stage IV, and five Stage II patients (i.e., 11) survived > 10 to > 18 years. Five others are alive but have not reached 10 years; three of them have no evidence of disease (NED). Three patients died of CA before reaching 10 years. An additional three breast CA patients are being treated for > 2 years, but, < 5 years postoperatively, they are NED. The vaccination are presented as a delayed-type hypersensitivity reaction with significant inflammation with increase of helper T lymphocytes and decrease of T suppressor/cytotoxic cell ratio.
自1974年至1993年3月，我们使用T/Tn抗原疫苗对晚期乳腺癌（CA）复发进行安全、特异、有效、长期的皮内接种。分期采用病理TNM系统。治疗是无限期的。在连续接种疫苗的19例乳腺癌患者中，6例IV期、6例III期和7例II期患者术后均存活超过5年。3例III期、3例IV期和5例II期患者（即11例）存活超过10至18年。另外5例患者存活但未达10年；其中3例无疾病证据（NED）。3例患者在10年之前死于CA。另有3例乳腺癌患者接受治疗超过2年，但术后不到5年，他们处于NED状态。接种疫苗表现为迟发型超敏反应，伴有明显炎症，辅助性T淋巴细胞增加，T抑制/细胞毒性细胞比例降低。
